Noema Pharma needs to up their game on announcing/publishing results

Noema Pharma needs to up their game on announcing/publishing results This company ran the Orpheus trial for gemlapodect. This came following the failure of ecopipam. The phase 2b stage for gemlapodect ended OVER A YEAR AGO, and there's been no results communication as far as I can tell. It shouldn't take this long to conclude whether or not the efficacy of the drug warrants progression to phase 3. This makes me wonder if gemlapodect also failed the test because if there was good news it would behoove Noema to report it ASAP.